Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Up 75.1% in January

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 41,500 shares, a growth of 75.1% from the January 15th total of 23,700 shares. Approximately 2.6% of the shares of the stock are short sold. Based on an average trading volume of 299,700 shares, the days-to-cover ratio is currently 0.1 days.

Sonoma Pharmaceuticals Trading Down 1.0 %

NASDAQ:SNOA traded down $0.03 during midday trading on Thursday, hitting $2.52. 28,405 shares of the stock were exchanged, compared to its average volume of 49,869. The business has a 50-day moving average price of $2.67 and a two-hundred day moving average price of $2.44. The company has a market capitalization of $4.07 million, a price-to-earnings ratio of -0.63 and a beta of 1.43. Sonoma Pharmaceuticals has a one year low of $2.44 and a one year high of $9.37.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings data on Wednesday, February 5th. The company reported ($0.59) EPS for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 68.98% and a negative net margin of 26.82%. Sell-side analysts forecast that Sonoma Pharmaceuticals will post -0.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC acquired a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned about 1.08% of Sonoma Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.